Systemic Sclerosis Pathogenesis and Emerging Therapies, Beyond the Fibroblast

BioMed Research International - United States
doi 10.1155/2019/4569826
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

Biomarkers Inform Clinical Trials and Pathogenesis in Systemic Sclerosis

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2010English

Toll Like Receptors in Systemic Sclerosis: An Emerging Target

Immunology Letters
AllergyImmunology
2018English

Nintedanib Inhibits Fibroblast Activation and Ameliorates Fibrosis in Preclinical Models of Systemic Sclerosis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2015English

The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis

Frontiers in Immunology
AllergyImmunology
2019English

698 Novel Immunomodulatory Therapies for Systemic Sclerosis (SSc) Using Biodegradable Nanoparticles

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

The Role of T Lymphocytes in the Pathogenesis of Systemic Sclerosis and New Therapeutic Perspectives

Forum Reumatologiczne
2019English

Emerging Therapies

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2001English

Role of Growth Factors in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis

Current Rheumatology Reviews
Rheumatology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy